Mya Symons
Mya Symons
- Messages
- 1,029
- Location
- Washington
I was watching the video of the CFSAC speakers and noticed that one speaker mentioned an outbreak of Adeno virus that triggered her illness. This was the same trigger for my son. I know this because a couple weeks after he started having seizures he came down with a high fever. At that point, the doctors at Children's Hospital in Seattle checked him for viruses and found an Adeno Virus. I was wondering if there could be a connection between an Adeno Virus and a Retrovirus infection that is causing CFS/ME. I found the following abstract of a medical journal article. It seems they were trying to use the two viruses together for gene therapy since alone they weren't doing the job. COULD IT BE POSSIBLE THAT A PERSON COULD CARRY SOMETHING LIKE XMRV FOR YEARS AND NOT GET SICK UNTIL IT IS TRIGGERED BY AN ADENO VIRUS (a DNA virus)--WHICH THEN ALLOWS IT TO ENTER THE CELLS AND REPRODUCE?
After you read this, can you bump the jokes back up? We need jokes.
Gene Ther. 1998 Sep;5(9):1251-8.
Construction of new retroviral producer cells from adenoviral and retroviral vectors.
Lin X.
Source
Protein Studies Program, Oklahoma Medical Research Foundation, Oklahoma City 73104, USA.
Abstract
A combination of adenoviral and retroviral vectors was used to construct second generation packaging cells that deliver marker genes to target cells. A vector based upon Moloney murine leukemia virus (MoMLV) was used to deliver marker genes, and an adenovirus-based delivery system was used to deliver MoMLV structural genes (gag pol and env) to cultured cells. The procedure transformed the cells into new retroviral producer cells, which generate replication-incompetent retroviral particles in the culture supernatant for transferring marker genes to target cells. The titer of the retroviral-containing supernatant generated from the second generation producer cells reached above 10(5) c.f.u./ml, which is comparable to the MoMLV-based producer cell lines currently used in human gene therapy trials. These observations suggest that this new gene transfer scheme is technically feasible. The vector and procedures may be adapted for experimental human gene therapy in which the new producer cells are transplanted into patients for continuous gene transfer.
PMID: 9930327 [PubMed - indexed for MEDLINE] Free Article
HERE'S ANOTHER STUDY WHERE THEY TALK ABOUT A REPLICATION-COMPETENT HYBRID OF THE ADENO VIRUS AND AN MuLv:
Mol Ther. 2011 Jan;19(1):76-82. Epub 2010 Aug 31.
Adenovirus-retrovirus hybrid vectors achieve highly enhanced tumor transduction and antitumor efficacy in vivo.
Kubo S, Haga K, Tamamoto A, Palmer DJ, Ng P, Okamura H, Kasahara N.
Source
Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan. s-kubo@hyo-med.ac.jp
Abstract
Murine leukemia virus (MLV)-based replication-competent retrovirus (RCR) vectors have been shown to mediate efficient, selective, and persistent tumor transduction, thereby achieving significant therapeutic benefit in a wide variety of cancer models. To further augment the efficiency of this strategy, we have developed a delivery method employing a gutted adenovirus encoding an RCR vector (AdRCR); thus, tumor cells transduced with the adenoviral vector transiently become RCR vector producer cells in situ. As expected, high-titer AdRCR achieved significantly higher initial transduction levels in human cancer cells both in vitro and in vivo, as compared to the original RCR vector itself. Notably, even at equivalent initial transduction levels, more secondary RCR progeny were produced from AdRCR-transduced cells as compared to RCR-transduced cells, resulting in further acceleration of subsequent RCR replication kinetics. In pre-established tumor models in vivo, prodrug activator gene therapy with high-titer AdRCR could achieve enhanced efficacy compared to RCR alone, in a dose-dependent manner. Thus, AdRCR hybrid vectors offer the advantages of high production titers characteristic of adenovirus and secondary production of RCR in situ, which not only accelerates subsequent vector spread and progressive tumor transduction, but can also significantly enhance the therapeutic efficacy of RCR-mediated prodrug activator gene therapy.
PMID: 20808291 [PubMed - indexed for MEDLINE] PMCID: PMC3017434 [Available on 2012/1/4]
After you read this, can you bump the jokes back up? We need jokes.
Gene Ther. 1998 Sep;5(9):1251-8.
Construction of new retroviral producer cells from adenoviral and retroviral vectors.
Lin X.
Source
Protein Studies Program, Oklahoma Medical Research Foundation, Oklahoma City 73104, USA.
Abstract
A combination of adenoviral and retroviral vectors was used to construct second generation packaging cells that deliver marker genes to target cells. A vector based upon Moloney murine leukemia virus (MoMLV) was used to deliver marker genes, and an adenovirus-based delivery system was used to deliver MoMLV structural genes (gag pol and env) to cultured cells. The procedure transformed the cells into new retroviral producer cells, which generate replication-incompetent retroviral particles in the culture supernatant for transferring marker genes to target cells. The titer of the retroviral-containing supernatant generated from the second generation producer cells reached above 10(5) c.f.u./ml, which is comparable to the MoMLV-based producer cell lines currently used in human gene therapy trials. These observations suggest that this new gene transfer scheme is technically feasible. The vector and procedures may be adapted for experimental human gene therapy in which the new producer cells are transplanted into patients for continuous gene transfer.
PMID: 9930327 [PubMed - indexed for MEDLINE] Free Article
HERE'S ANOTHER STUDY WHERE THEY TALK ABOUT A REPLICATION-COMPETENT HYBRID OF THE ADENO VIRUS AND AN MuLv:
Mol Ther. 2011 Jan;19(1):76-82. Epub 2010 Aug 31.
Adenovirus-retrovirus hybrid vectors achieve highly enhanced tumor transduction and antitumor efficacy in vivo.
Kubo S, Haga K, Tamamoto A, Palmer DJ, Ng P, Okamura H, Kasahara N.
Source
Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan. s-kubo@hyo-med.ac.jp
Abstract
Murine leukemia virus (MLV)-based replication-competent retrovirus (RCR) vectors have been shown to mediate efficient, selective, and persistent tumor transduction, thereby achieving significant therapeutic benefit in a wide variety of cancer models. To further augment the efficiency of this strategy, we have developed a delivery method employing a gutted adenovirus encoding an RCR vector (AdRCR); thus, tumor cells transduced with the adenoviral vector transiently become RCR vector producer cells in situ. As expected, high-titer AdRCR achieved significantly higher initial transduction levels in human cancer cells both in vitro and in vivo, as compared to the original RCR vector itself. Notably, even at equivalent initial transduction levels, more secondary RCR progeny were produced from AdRCR-transduced cells as compared to RCR-transduced cells, resulting in further acceleration of subsequent RCR replication kinetics. In pre-established tumor models in vivo, prodrug activator gene therapy with high-titer AdRCR could achieve enhanced efficacy compared to RCR alone, in a dose-dependent manner. Thus, AdRCR hybrid vectors offer the advantages of high production titers characteristic of adenovirus and secondary production of RCR in situ, which not only accelerates subsequent vector spread and progressive tumor transduction, but can also significantly enhance the therapeutic efficacy of RCR-mediated prodrug activator gene therapy.
PMID: 20808291 [PubMed - indexed for MEDLINE] PMCID: PMC3017434 [Available on 2012/1/4]